The latest financial statements from Merck, the manufacturer of the NuvaRing, appear to show that the warnings and surrounding litigation are slowing the drug’s use. According to a report on DrugRisk, an online pharmaceutical resource center, sales slipped by 2% from 2011. The drop is not surprising. Additionally, the New England Journal of Medicine and British Medical Journal have published studies finding vaginal ring contraceptives, like the NuvaRing, could relate to “2.5 to 3 fold increased risk of blood clots over traditional pills.”

NuvaRing users continue to suffer negative health effects that can be fatal including strokes, DVT and pulmonary embolisms. There are more than 1,000 NuvaRing cases currently pending across the country.  The first New Jersey trial is scheduled to begin in May, 2013.

If you, or someone you know, has experienced adverse effects as a result of using Nuvaring®, you can contact Stark & Stark and speak to one of the Mass Tort/Pharmaceutical Litigation attorneys, free of charge, who can help assess any claims that you might have against the manufacturer of NuvaRing®.